Lower-intensity chemo before stem cell transplant for MDS
Part of Cancer clinical trials.
This study tests a less intense chemotherapy conditioning regimen before a stem cell transplant in people with myelodysplastic syndromes (MDS), a type of blood cancer where the bone marrow doesn't make enough healthy blood cells. The aim is to see if this approach is safer and still works well, potentially helping more people qualify for transplant.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 14 and 70 years old.
- You have a confirmed diagnosis of MDS (myelodysplastic syndrome).
- Your MDS is considered intermediate or high risk on standard scoring systems, or you need regular blood transfusions.
- You are generally able to care for yourself and are not bedridden (ECOG score of 3 or less).
- Your heart, liver, and kidney function are adequate, as shown by recent blood tests and a heart ultrasound.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a stem cell transplant using milder chemotherapy (treosulfan and fludarabine) followed by a drug called cyclophosphamide to prevent graft-versus-host disease. It aims to make transplant safer for people with blood diseases who cannot handle standard high-dose chemotherapy.
This trial compares two drug combinations used before a stem cell transplant to see which is safer and more effective for people with acute myeloid leukemia (AML) that is in remission but still has minimal residual disease (MRD). The goal is to help prevent the leukemia from coming back after transplant.
This trial tests a stronger chemotherapy combination before a donor stem cell transplant for people with certain blood cancers (like AML, MDS, or CMML) that have spread to other parts of the body, such as the skin, testicles, or central nervous system. The goal is to see if this approach can improve outcomes for patients whose disease is in remission.
This trial tests whether a less intense chemotherapy and transplant plan can work for adults with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) who are getting a stem cell transplant. It may help reduce transplant-related harm, especially in people considered higher risk due to age or other health factors.
This trial tests a stronger chemo and radiation plan before a stem cell transplant for people with myelodysplastic syndrome (a blood disorder) or acute myeloid leukemia (a blood cancer). The goal is to help the transplant work better and reduce the chance of the disease coming back.
This trial tests a less intense chemotherapy and radiation combination (called TMLI, fludarabine, and melphalan) before a stem cell transplant from a matched donor. The goal is to help prepare your body for the transplant while reducing side effects, so it may be a good option if you have high-risk MDS or AML and cannot tolerate the standard, more intensive conditioning regimen.
Hear when a new MDS trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.